Esperion Therapeutics, Inc.

Esperion Therapeutics develops medicines for patients with elevated LDL-C. Marketed products include NEXLETOL and NEXLIZET tablets for primary hyperlipidemia treatment. The company also has NILEMDO, an ACL inhibitor, and NUSTENDI, a bempedoic acid and ezetimibe tablet. Esperion has agreements with Daiichi Sankyo, Otsuka Pharmaceutical, and Daiichi Sankyo Europe. Founded in 2008, the company is headquartered in Ann Arbor, Michigan.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

2.1 USD

Potential

-100%

Strengths

The company has high returns. ROIC (25.96%) is higher than the sector mean (14.71%).
EV/EBITDA (8.93) is lower than the sector mean (51.86).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	9.0
Price/Free Cash Flow'	100.0
ROIC	26.0%
Net Debt/EBITDA	2.4